Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E.

J Clin Psychopharmacol. 2002 Aug;22(4):419-23.

PMID:
12172343
2.

Plasma risperidone concentrations during combined treatment with sertraline.

Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A.

Ther Drug Monit. 2004 Aug;26(4):386-90.

PMID:
15257068
3.

Risperidone plasma levels, clinical response and side-effects.

Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. Epub 2004 Nov 29.

PMID:
15565299
4.

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.

Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A.

Ther Drug Monit. 2001 Jun;23(3):223-7.

PMID:
11360029
5.

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.

Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY.

Clin Pharmacol Ther. 2005 Nov;78(5):520-8. Epub 2005 Sep 26.

PMID:
16321618
6.

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E.

Psychopharmacology (Berl). 2001 Jan 1;153(2):238-43.

PMID:
11205425
7.

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML.

Psychopharmacology (Berl). 1999 Dec;147(3):300-5.

PMID:
10639689
8.

Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.

Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, De Vries R, Kaneko S.

J Clin Pharmacol. 2002 Oct;42(10):1083-8.

PMID:
12362921
9.

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T.

J Clin Pharmacol. 2003 Feb;43(2):122-7.

PMID:
12616663
10.

No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A.

Ther Drug Monit. 2001 Dec;23(6):675-8.

PMID:
11802103
11.

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E.

Ther Drug Monit. 2000 Aug;22(4):481-5.

PMID:
10942191
12.

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Fabrazzo M, Monteleone P, Maj M, Perucca E, Caputi AP.

Int Clin Psychopharmacol. 1998 May;13(3):141-5.

PMID:
9690983
13.

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, Kim YK, Kim SH, Han C, Lee MS, Park JY.

J Clin Psychopharmacol. 2009 Jun;29(3):272-7. doi: 10.1097/JCP.0b013e3181a289e0.

PMID:
19440082
14.

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.

Berecz R, LLerena A, de la Rubia A, Gómez J, Kellermann M, Dorado P, Degrell I.

Pharmacopsychiatry. 2002 Nov;35(6):231-4.

PMID:
12518271
15.

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.

Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L.

Eur J Clin Pharmacol. 2001 Nov;57(9):671-5.

PMID:
11791898
16.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
17.

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP.

Ther Drug Monit. 1999 Feb;21(1):105-15.

PMID:
10051063
18.

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L.

J Psychopharmacol. 2007 Nov;21(8):837-42. Epub 2007 Aug 22.

PMID:
17715206
19.

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.

Int Clin Psychopharmacol. 2005 Mar;20(2):71-8.

PMID:
15729081
20.

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P.

Pharmacopsychiatry. 2002 Mar;35(2):50-6.

PMID:
11985287
Items per page

Supplemental Content

Write to the Help Desk